• Top Stories
  • Interviews
  • Business
  • Finance
  • Banking
  • Technology
  • Investing
  • Trading
  • Videos
  • Awards
  • Magazines
  • Headlines
  • Trends
Close Search
00
GBAF LogoGBAF Logo
  • Top Stories
  • Interviews
  • Business
  • Finance
  • Banking
  • Technology
  • Investing
  • Trading
  • Videos
  • Awards
  • Magazines
  • Headlines
  • Trends
GBAF Logo
  • Top Stories
  • Interviews
  • Business
  • Finance
  • Banking
  • Technology
  • Investing
  • Trading
  • Videos
  • Awards
  • Magazines
  • Headlines
  • Trends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking and Finance Review

Global Banking & Finance Review

Company

    GBAF Logo
    • About Us
    • Profile
    • Wealth
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2025 GBAF Publications Ltd - All Rights Reserved.

    ;
    Editorial & Advertiser disclosure

    Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Top Stories

    Posted By Jessica Weisman-Pitts

    Posted on September 19, 2024

    Featured image for article about Top Stories

    LONDON (Reuters) -Bavarian Nordic said on Thursday its mpox vaccine was approved by the EU’s drug regulator for use in adolescents, bolstering the case for using the shot in the 12 to 17 age group to contain an outbreak in parts of Africa.

    Mpox has been declared a global public health emergency by the World Health Organization (WHO), with children and adolescents being particularly vulnerable to the disease.

    Bavarian’s JYNNEOS has also been approved by the U.S. Food and Drug Administration (FDA) but only for adults 18 years and older, although it granted an Emergency Use Authorization for its use in adolescents during the mpox outbreak of 2022.

    Its approval by the Committee for Medicinal Products for Human Use (CHMP), draws on data submitted by the Danish biotech firm to the European Medicines Agency (EMA) last month.

    “We applaud EMA for their expedited review and decision to recommend approval,” said Bavarian CEO Paul Chaplin.

    While the WHO says the vaccine can be used “off-label” for people below 18, it has only backed its use in adults.

    WHO approval can guide domestic choices, as well as allowing international aid groups to buy and distribute a vaccine.

    Democratic Republic of Congo (DRC), worst-hit by the current outbreak, is not planning to vaccinate under-18 year olds in its first wave of immunisations with the Bavarian vaccine.

    Another mpox vaccine, made by the Japan’s KM Biologics, can already be given to children, according to the Japanese regulator, although it requires a special kind of needle.

    While the EMA decision does not officially guide countries outside Europe, Congo referred to its evaluation of Bavarian’s vaccine in its June emergency use approval of the shot domestically. It also mentioned the FDA approval.

    Since this outbreak began in January, there have been nearly 25,100 cases and more than 720 deaths in Africa, where the country reporting the most cases is the DRC, the WHO says.

    (Reporting by Maggie Fick, editing by Terje Solsvik and Alexander Smith)

    Recommended for you

    • Thumbnail for recommended article

    • Thumbnail for recommended article

    • Thumbnail for recommended article

    Why waste money on news and opinions when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe